Neuronetics (STIM) Set to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Neuronetics to post earnings of ($0.33) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $20.31 million for the quarter, compared to analyst estimates of $19.73 million. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. During the same period in the previous year, the firm earned ($0.30) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Performance

Shares of STIM opened at $3.81 on Monday. The business’s 50-day moving average is $3.96 and its 200-day moving average is $2.93. The company has a current ratio of 4.73, a quick ratio of 4.33 and a debt-to-equity ratio of 1.73. Neuronetics has a fifty-two week low of $1.03 and a fifty-two week high of $5.07.

Insider Buying and Selling

In other Neuronetics news, EVP William Andrew Macan sold 15,621 shares of Neuronetics stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $3.38, for a total value of $52,798.98. Following the completion of the sale, the executive vice president now directly owns 417,736 shares in the company, valued at $1,411,947.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP William Andrew Macan sold 15,621 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $3.38, for a total transaction of $52,798.98. Following the transaction, the executive vice president now owns 417,736 shares in the company, valued at approximately $1,411,947.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Furlong sold 14,710 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $3.51, for a total transaction of $51,632.10. Following the completion of the sale, the chief financial officer now owns 509,033 shares of the company’s stock, valued at $1,786,705.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 150,279 shares of company stock worth $489,167. Insiders own 9.80% of the company’s stock.

Analyst Upgrades and Downgrades

STIM has been the topic of several research reports. William Blair reiterated a “market perform” rating on shares of Neuronetics in a research note on Tuesday, March 26th. Piper Sandler reiterated an “overweight” rating and set a $8.00 price objective (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.